Assessing nivolumab in class II expressing microsatellite stable (pMMR) colorectal cancer (CRC): Results of the ANICCA-Class II trial
Authors
Middleton, G.Liu, W.
Savage, J.
Bridgewater, J. A.
Ross, P.
Saunders, Mark P
Plummer, R.
Clive, S.
Coyle, V.
Thomas, A.
Taniere, P.
Billingham, L.
Affiliation
Institute Of Immunology And Immunotherapy, University of Birmingham,Issue Date
2022
Metadata
Show full item recordCitation
Middleton G, Liu W, Savage J, Bridgewater JA, Ross P, Saunders MP, et al. Assessing nivolumab in class II expressing microsatellite stable (pMMR) colorectal cancer (CRC): Results of the ANICCA-Class II trial. Annals of Oncology. 2022 Sep;33(7):S729-S30. PubMed PMID: WOS:000866211600420.Journal
Annals of OncologyDOI
10.1016/annonc/annonc1048Additional Links
https://dx.doi.org/10.1016/annonc/annonc1048Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/annonc/annonc1048